Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12565
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Woods, Katherine | en |
dc.contributor.author | Pasam, Anupama | en |
dc.contributor.author | Jayachandran, Aparna | en |
dc.contributor.author | Andrews, Miles C | en |
dc.contributor.author | Cebon, Jonathan S | en |
dc.date.accessioned | 2015-05-16T02:16:47Z | - |
dc.date.available | 2015-05-16T02:16:47Z | - |
dc.date.issued | 2014-12-17 | en |
dc.identifier.citation | Frontiers in Oncology 2014; 4(): 367 | en |
dc.identifier.govdoc | 25566505 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12565 | en |
dc.description.abstract | Melanoma cells can switch phenotype in a manner similar to epithelial to mesenchymal transition (EMT). In this perspective article, we address the effects of such phenotype switching on T cell targeting of tumor cells. During the EMT-like switch in phenotype, a concomitant change in expression of multiple tumor antigens occurs. Melanoma cells undergoing EMT escape from killing by T cells specific for antigens whose expression is downregulated by this process. We discuss melanoma antigens whose expression is influenced by EMT. We assess the effect of changes in the expressed tumor antigen repertoire on T-cell mediated tumor recognition and killing. In addition to escape from T cell immunity via changes in antigen expression, mesenchymal-like melanoma cells are generally more resistant to classical chemotherapy and radiotherapy. However, we demonstrate that when targeting antigens whose expression is unaltered during EMT, the capacity of T cells to kill melanoma cell lines in vitro is not influenced by their phenotype. When considering immune therapies such as cancer vaccination, these data suggest escape from T cell killing due to phenotype switching in melanoma could potentially be avoided by careful selection of target antigen. | en |
dc.language.iso | en | en |
dc.subject.other | T cell killing | en |
dc.subject.other | T-lymphocytes | en |
dc.subject.other | cancer testis antigens | en |
dc.subject.other | epithelial–mesenchymal transition | en |
dc.subject.other | Melanoma | en |
dc.subject.other | tumor antigens | en |
dc.title | Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Frontiers in oncology | en |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Cancer Immunobiology Laboratory,Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.3389/fonc.2014.00367 | en |
dc.description.pages | 367 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/25566505 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Cebon, Jonathan S | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.